<DOC>
	<DOCNO>NCT00776867</DOCNO>
	<brief_summary>The purpose study test whether perifosine- drug inhibits protein AKT , success treatment adult cancers- safe effective treating cancer . The investigator want find effect , good and/or bad , patient cancer . The investigator test different dose schedule perifosine patient ask partake one dose schedule .</brief_summary>
	<brief_title>Study Single Agent Perifosine Recurrent Pediatric Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Any solid tumor fail standard therapy . Patient must evidence tumor CT , MRI , PET scan , MIBG scan , serum marker , tissue sampling . Age ≤ 21 year . Karnofsky/Lansky performance status ≥ 50 % ( Karnofsky score age &gt; 16 year Lansky score age ≤ 16 year ) ANC≥ 1000 least 24 hour GCSF Platelets ≥ 75k least one week platelet transfusion Hg≥ 8g/dL least one week PRBC transfusion AST ≤ 3 x upper limit normal ALT ≤ 3 x upper limit normal Total bilirubin ≤ 2.0 mg/dl serum creatinine ≤ 1.5 x upper limit normal age , calculate creatinine clearance nuclear GFR ≥ 70 ml/min/1.73 m2 . ≥ 3 week since last nonnitrosourea chemotherapy ≥ 6 week since last nitrosoureas ≥ 4 week since last RT Patients must agree practice adequate contraception . Females childbearing potential must negative BHCG pregnancy test document within 14 day prior drug initiation . Females must breast feeding . Patients must able swallow tablet whole Pregnancy Patients must active infection serious intercurrent medical illness . HIVPositive patient receive combination antiretroviral therapy exclude study due possible retroviral drug interaction . HIV test require . Patients must take EIAEDs . If patient previously EIAEDs discontinue , patient must agent least 2 week prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Pediatric solid tumor</keyword>
	<keyword>08-091</keyword>
</DOC>